YANKCOM Partnership Invests $398,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

YANKCOM Partnership purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 765 shares of the medical research company’s stock, valued at approximately $398,000.

A number of other institutional investors have also recently made changes to their positions in TMO. Legacy Investment Solutions LLC bought a new stake in Thermo Fisher Scientific in the 3rd quarter worth $26,000. Peterson Financial Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth about $27,000. Missouri Trust & Investment Co purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. Finally, Decker Retirement Planning Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $43,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of research analyst reports. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. TD Cowen lifted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Finally, Barclays reduced their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 8th. The stock was sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares in the company, valued at approximately $8,076,178.88. The trade was a 38.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,125 shares of company stock valued at $16,207,439 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.2 %

Shares of NYSE:TMO opened at $581.72 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The stock’s fifty day moving average price is $544.31 and its 200-day moving average price is $571.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $222.51 billion, a P/E ratio of 35.19, a PEG ratio of 4.06 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.29 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.